Gyre Therapeutics, Inc. GYRE GNI — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gni — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s GNI — research and development expense?
- Gyre Therapeutics, Inc. (GYRE) reported GNI — research and development expense of $0 in Q1 2026.
- What is the long-term trend for Gyre Therapeutics, Inc.'s GNI — research and development expense?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s GNI — research and development expense has grown at a -100.0% compound annual growth rate (CAGR), from $2.6M to $0.
- What does GNI — research and development expense mean?
- Captures the costs incurred for research and development activities specifically attributable to the GNI segment. These expenses include personnel, clinical trial costs, and laboratory resources dedicated to advancing product candidates within this segment. Monitoring this helps investors assess the company's commitment to innovation and the pace of its pipeline development.